Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial

被引：0

作者：

Harry D. Bear

John Roberts

David Cornell

Mary Beth Tombes

Brenda Kyle

机构：

[1] Massey Cancer Center,

[2] Medical College of Virginia,undefined

[3] Virginia Commonwealth University,undefined

[4] Richmond,undefined

[5] USA,undefined

[6] Department of Medicine,undefined

[7] Medical College of Virginia,undefined

[8] Virginia Commonwealth University,undefined

[9] Richmond,undefined

[10] USA,undefined

[11] Department of Surgery,undefined

[12] Lincoln Hospital and Cornell University School of Medicine,undefined

[13] Division of Surgical Oncology,undefined

[14] Virginia Commonwealth University,undefined

[15] Box 980011,undefined

[16] Richmond,undefined

[17] VA 23298-0011,undefined

[18] USA e-mail: hbear@hsc.vcu.edu Tel.: +1-804-8289325; Fax: +1-804-8284808,undefined

来源：

Cancer Immunology, Immunotherapy | 2001年 / 50卷

关键词：

Key words Immunotherapy; Lymphocytes; Bryostatin 1; Ionomycin; Interleukin-2;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Adoptive immunotherapy (AIT) of cancer with T lymphocytes may be limited by the need to activate tumor antigen-sensitized cells in vitro. In murine models, we have shown that AIT with tumor-sensitized T cells that have been pharmacologically activated with bryostatin 1 and ionomycin plus interleukin-2 can induce tumor regression. A Phase I clinical trial was carried out to assess the feasibility and toxicity associated with using tumor- or vaccine-draining lymph node cells, activated pharmacologically and expanded in culture with low-dose interleukin-2 and infused intravenously, followed by IL-2 infusion. Nine patients were entered into the trial, and six were treated as planned. Average expansion of cell numbers over 13 to 27 days in culture was 118-fold. No patient's cells reached the target cell number (2.5 × 1010). Infusion of these cells did not result in any unexpected toxicities. The toxicities observed were related to IL-2 infusion, and conformed to the expected range of side-effects. Based on these Phase I results, additional trials, with tumor antigen vaccine-sensitized DLN and technical modifications of the culture technique, are planned.

引用

页码：269 / 274

页数：5